- Pacific Biosciences of California, Inc. has raised a significant amount of cash through debt and share issuance in the last two years.
- The company continues to burn through cash and there seems to be no end in site despite recent revenue growth.
- Oxford Nanopore Technologies and other competitors are starting to encroach on PacBio's niche in the long-read sequencing space.
- There was a ~10% short position in the company at the end of October.
- Alternative names in the life science space offer a more compelling investment thesis.
For further details see:
10% Short Interest In Pacific Biosciences Makes Sense